KA/EN
Register
Medicines reference
Search
Search
Product

Ataxxa

Favourites

Permethrin + Imidacloprid · KRKA

4 forms: spot-on. In force in Georgia: 4 of 4 (veterinary register).

Do not use on cats. Prevent cats from contacting or grooming a treated dog; follow the exact label for the separation period. Species safety: cats →

Forms and doses4 of 4 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Weight Dose Frequency Georgia
200 mg/40 mg, Spot-on · Cat Any weight Cat Any weight No dose for this species
Do not use this product in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 174-11
Verified on: 15 Oct 2026
200 mg/40 mg, Spot-on · Dog 1.5–4 kg Dog 1.5–4 kg 1 pipette
<= 4 kg Ataxxa 200 mg/40 mg spot-on solution for dogs up to 4 kg 0.4 ml minimum of 10 [mg/kg imidacloprid] minimum of 50 [mg/kg permethrin] The interval between two treatments should be 4 weeks. do not use the veterinary medicinal product on puppies of less than 7 weeks of age, or 1.5 kg of weight. Do not use on cats.
 · every 4 weeks		 every 4 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 174-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ataxxa 200 mg/40 mg, Spot-on

permethrin 200 mg + imidacloprid 40 mg, spot-on solution for dogs up to 4 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Ataxxa

200 mg/40 mg, permethrin 200 mg + imidacloprid 40 mg, spot-on solution for dogs up to 4 kg
Assessed clinical scopeDog · Full canine label: flea treatment/prevention and FAD strategy, persistent tick control, labelled repellency against Ixodes ticks, sand flies and Aedes mosquitoes, and indirect reduction of Leishmania infantum transmission risk · On the skin
Care settingExact weight-band monthly pipette after weighing and parasite-risk assessment; apply to one intact-skin site, prevent licking and separate from cats until dry
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 174-11 · Verified on 15 Oct 2026

A well-documented broad canine ectoparasiticide with exact-product flea and tick studies plus useful vector repellency. Choose it for the combined clinical role, respect the delayed or incomplete protection against some vectors, and treat feline exposure prevention as mandatory.

Regulatory and scientific credibility9.0/10

All four exact presentations are registered in Georgia and covered by current regulator-hosted product literature, valid multinational authorisations and a transparent exact-product hybrid dossier with dose-confirmation studies.

Clinical efficacy8.5/10

Exact-product GCP studies support four-week flea activity and persistent efficacy against the labelled ticks, while applicable controlled and field studies support the imidacloprid-permethrin vector role. Immediate tick efficacy was not demonstrated, duration varies by target and bites or transmission are not completely prevented.

Safety and tolerability7.5/10

Healthy dogs tolerated the label dose and even five-fold overdose well in the dossier, with very rare canine reactions. The clinically important limits are potentially fatal feline permethrin exposure, reproductive uncertainty linked to N-methylpyrrolidone and aquatic toxicity.

Clinical practicality8.5/10

A single-site weight-band pipette provides roughly monthly control and is straightforward, but drying, cat separation, bathing timing, vector-onset limitations and seasonal repeat treatment still require planning.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never use on cats. Permethrin exposure is extremely poisonous and can be fatal; keep treated dogs away until the site is dry and seek veterinary advice immediately if a cat contacts or grooms it.
  • Do not use below seven weeks of age, outside the exact presentation weight band or in known hypersensitivity. Weigh accurately and apply only to intact skin.
  • Single ticks or vector bites may still occur and pathogen transmission cannot be excluded. Mosquito repellency begins at day 7; keep dogs protected during the first 24 hours after the initial application for the Leishmania-risk claim.
  • Ticks already present may remain attached and alive for two days; remove them manually. Exact-product studies did not demonstrate immediate tick efficacy.
  • Very rare reactions include local pruritus, erythema, oedema or hair loss, behavioural or gastrointestinal signs and neurologic signs. Prevent licking; oral exposure may cause vomiting, tremor or incoordination.
  • Safety in pregnancy, lactation and breeding animals is not established, and N-methylpyrrolidone was foetotoxic in laboratory species; use only after veterinary benefit-risk assessment and consult before use in sick or debilitated dogs.
  • Keep treated dogs out of surface water for 48 hours. Frequent or prolonged water exposure may reduce persistence, shampoo should be used before treatment or at least two weeks later, and post-wetting tick efficacy is unstudied.
  • No medicinal interactions or major incompatibilities are known in the current product literature.
Assessment sources
  1. VMD Ataxxa product literature2026
  2. VMD Ataxxa assessment2018
  3. European tick field RCT2016
  4. Vector-borne disease field study2010
  5. Canine leishmaniosis field trial2007
  6. Sand-fly repellent study2007
  7. Mosquito repellent study2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Permethrin200 mg Imidacloprid40 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
KRKA · Slovenia
Manufacturer (register)
KRKA, d.d., Novo mesto, Slovenia
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1113, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 174-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Do not use this product in cats.
 Cat Any weight On the skin - Product label (SPC)
1 pipette
<= 4 kg Ataxxa 200 mg/40 mg spot-on solution for dogs up to 4 kg 0.4 ml minimum of 10 [mg/kg imidacloprid] minimum of 50 [mg/kg permethrin] The interval between two treatments should be 4 weeks. do not use the veterinary medicinal product on puppies of less than 7 weeks of age, or 1.5 kg of weight. Do not use on cats.
 Dog 1.5–4 kg On the skin every 4 weeks Product label (SPC)
500 mg/100 mg, Spot-on · Cat Any weight Cat Any weight No dose for this species
Do not use this product in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 157-11
Verified on: 15 Oct 2026
500 mg/100 mg, Spot-on · Dog 4–10 kg Dog 4–10 kg 1 pipette
>4 kg <= 10 kg Ataxxa 500 mg/100 mg... 1.0 ml 10 - 25 [mg/kg imidacloprid] 50 - 125 [mg/kg permethrin]
 · every 4 weeks		 every 4 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 157-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ataxxa 500 mg/100 mg, Spot-on

permethrin 500 mg + imidacloprid 100 mg, spot-on solution for dogs 4-10 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.4/10
Very good
vetman assessment

Ataxxa

500 mg/100 mg, permethrin 500 mg + imidacloprid 100 mg, spot-on solution for dogs 4-10 kg
Assessed clinical scopeDog · Full canine label: flea treatment/prevention and FAD strategy, persistent tick control, labelled repellency against Ixodes ticks, sand flies and Aedes mosquitoes, and indirect reduction of Leishmania infantum transmission risk · On the skin
Care settingExact weight-band monthly pipette after weighing and parasite-risk assessment; apply to one intact-skin site, prevent licking and separate from cats until dry
vetman score 8.4/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 157-11 · Verified on 15 Oct 2026

A well-documented broad canine ectoparasiticide with exact-product flea and tick studies plus useful vector repellency. Choose it for the combined clinical role, respect the delayed or incomplete protection against some vectors, and treat feline exposure prevention as mandatory.

Regulatory and scientific credibility9.0/10

All four exact presentations are registered in Georgia and covered by current regulator-hosted product literature, valid multinational authorisations and a transparent exact-product hybrid dossier with dose-confirmation studies.

Clinical efficacy8.5/10

Exact-product GCP studies support four-week flea activity and persistent efficacy against the labelled ticks, while applicable controlled and field studies support the imidacloprid-permethrin vector role. Immediate tick efficacy was not demonstrated, duration varies by target and bites or transmission are not completely prevented.

Safety and tolerability7.5/10

Healthy dogs tolerated the label dose and even five-fold overdose well in the dossier, with very rare canine reactions. The clinically important limits are potentially fatal feline permethrin exposure, reproductive uncertainty linked to N-methylpyrrolidone and aquatic toxicity.

Clinical practicality8.5/10

A single-site weight-band pipette provides roughly monthly control and is straightforward, but drying, cat separation, bathing timing, vector-onset limitations and seasonal repeat treatment still require planning.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never use on cats. Permethrin exposure is extremely poisonous and can be fatal; keep treated dogs away until the site is dry and seek veterinary advice immediately if a cat contacts or grooms it.
  • Do not use below seven weeks of age, outside the exact presentation weight band or in known hypersensitivity. Weigh accurately and apply only to intact skin.
  • Single ticks or vector bites may still occur and pathogen transmission cannot be excluded. Mosquito repellency begins at day 7; keep dogs protected during the first 24 hours after the initial application for the Leishmania-risk claim.
  • Ticks already present may remain attached and alive for two days; remove them manually. Exact-product studies did not demonstrate immediate tick efficacy.
  • Very rare reactions include local pruritus, erythema, oedema or hair loss, behavioural or gastrointestinal signs and neurologic signs. Prevent licking; oral exposure may cause vomiting, tremor or incoordination.
  • Safety in pregnancy, lactation and breeding animals is not established, and N-methylpyrrolidone was foetotoxic in laboratory species; use only after veterinary benefit-risk assessment and consult before use in sick or debilitated dogs.
  • Keep treated dogs out of surface water for 48 hours. Frequent or prolonged water exposure may reduce persistence, shampoo should be used before treatment or at least two weeks later, and post-wetting tick efficacy is unstudied.
  • No medicinal interactions or major incompatibilities are known in the current product literature.
Assessment sources
  1. VMD Ataxxa product literature2026
  2. VMD Ataxxa assessment2018
  3. European tick field RCT2016
  4. Vector-borne disease field study2010
  5. Canine leishmaniosis field trial2007
  6. Sand-fly repellent study2007
  7. Mosquito repellent study2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Permethrin500 mg Imidacloprid100 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
KRKA · Slovenia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 157-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Do not use this product in cats.
 Cat Any weight On the skin - Product label (SPC)
1 pipette
>4 kg <= 10 kg Ataxxa 500 mg/100 mg... 1.0 ml 10 - 25 [mg/kg imidacloprid] 50 - 125 [mg/kg permethrin]
 Dog 4–10 kg On the skin every 4 weeks Product label (SPC)
1250 mg/250 mg, Spot-on · Cat Any weight Cat Any weight No dose for this species
Do not use this product in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 175-11
Verified on: 15 Oct 2026
1250 mg/250 mg, Spot-on · Dog 10–25 kg Dog 10–25 kg 1 pipette
>10 kg <= 25 kg Ataxxa 1250 mg/250 mg... 2.5 ml 10 - 25 [mg/kg imidacloprid] 50 - 125 [mg/kg permethrin]
 · every 4 weeks		 every 4 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 175-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ataxxa 1250 mg/250 mg, Spot-on

permethrin 1250 mg + imidacloprid 250 mg, spot-on solution for dogs 10-25 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.3/10
Very good
vetman assessment

Ataxxa

1250 mg/250 mg, permethrin 1250 mg + imidacloprid 250 mg, spot-on solution for dogs 10-25 kg
Assessed clinical scopeDog · Full canine label: flea treatment/prevention and FAD strategy, persistent tick control, labelled repellency against Ixodes ticks, sand flies and Aedes mosquitoes, and indirect reduction of Leishmania infantum transmission risk · On the skin
Care settingExact weight-band monthly pipette after weighing and parasite-risk assessment; divide across four intact-skin sites, prevent licking and separate from cats until dry
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 175-11 · Verified on 15 Oct 2026

A well-documented broad canine ectoparasiticide with exact-product flea and tick studies plus useful vector repellency. Choose it for the combined clinical role, respect the delayed or incomplete protection against some vectors, and treat feline exposure prevention as mandatory.

Regulatory and scientific credibility9.0/10

All four exact presentations are registered in Georgia and covered by current regulator-hosted product literature, valid multinational authorisations and a transparent exact-product hybrid dossier with dose-confirmation studies.

Clinical efficacy8.5/10

Exact-product GCP studies support four-week flea activity and persistent efficacy against the labelled ticks, while applicable controlled and field studies support the imidacloprid-permethrin vector role. Immediate tick efficacy was not demonstrated, duration varies by target and bites or transmission are not completely prevented.

Safety and tolerability7.5/10

Healthy dogs tolerated the label dose and even five-fold overdose well in the dossier, with very rare canine reactions. The clinically important limits are potentially fatal feline permethrin exposure, reproductive uncertainty linked to N-methylpyrrolidone and aquatic toxicity.

Clinical practicality8.0/10

A weight-band pipette provides roughly monthly control, but four-site application, drying, cat separation, bathing timing, vector-onset limitations and seasonal repeat treatment add meaningful handling steps.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never use on cats. Permethrin exposure is extremely poisonous and can be fatal; keep treated dogs away until the site is dry and seek veterinary advice immediately if a cat contacts or grooms it.
  • Do not use below seven weeks of age, outside the exact presentation weight band or in known hypersensitivity. Weigh accurately and apply only to intact skin.
  • Single ticks or vector bites may still occur and pathogen transmission cannot be excluded. Mosquito repellency begins at day 7; keep dogs protected during the first 24 hours after the initial application for the Leishmania-risk claim.
  • Ticks already present may remain attached and alive for two days; remove them manually. Exact-product studies did not demonstrate immediate tick efficacy.
  • Very rare reactions include local pruritus, erythema, oedema or hair loss, behavioural or gastrointestinal signs and neurologic signs. Prevent licking; oral exposure may cause vomiting, tremor or incoordination.
  • Safety in pregnancy, lactation and breeding animals is not established, and N-methylpyrrolidone was foetotoxic in laboratory species; use only after veterinary benefit-risk assessment and consult before use in sick or debilitated dogs.
  • Keep treated dogs out of surface water for 48 hours. Frequent or prolonged water exposure may reduce persistence, shampoo should be used before treatment or at least two weeks later, and post-wetting tick efficacy is unstudied.
  • No medicinal interactions or major incompatibilities are known in the current product literature.
Assessment sources
  1. VMD Ataxxa product literature2026
  2. VMD Ataxxa assessment2018
  3. European tick field RCT2016
  4. Vector-borne disease field study2010
  5. Canine leishmaniosis field trial2007
  6. Sand-fly repellent study2007
  7. Mosquito repellent study2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Permethrin1250 mg Imidacloprid250 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
KRKA · Slovenia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 175-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Do not use this product in cats.
 Cat Any weight On the skin - Product label (SPC)
1 pipette
>10 kg <= 25 kg Ataxxa 1250 mg/250 mg... 2.5 ml 10 - 25 [mg/kg imidacloprid] 50 - 125 [mg/kg permethrin]
 Dog 10–25 kg On the skin every 4 weeks Product label (SPC)
2000 mg/400 mg, Spot-on · Cat Any weight Cat Any weight No dose for this species
Do not use this product in cats.
 - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 173-11
Verified on: 15 Oct 2026
2000 mg/400 mg, Spot-on · Dog 25–40 kg Dog 25–40 kg 1 pipette
>25 kg <= 40 kg Ataxxa 2000 mg/400 mg spot-on solution for dogs over 25 kg 4.0 ml 10 - 16 [mg/kg imidacloprid] 50 - 80 [mg/kg permethrin] For dogs > 40 kg the appropriate combination of pipettes should be used.
 · every 4 weeks		 every 4 weeks Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 173-11
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Ataxxa 2000 mg/400 mg, Spot-on

permethrin 2000 mg + imidacloprid 400 mg, spot-on solution for dogs 25-40 kg
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog
8.3/10
Very good
vetman assessment

Ataxxa

2000 mg/400 mg, permethrin 2000 mg + imidacloprid 400 mg, spot-on solution for dogs 25-40 kg
Assessed clinical scopeDog · Full canine label: flea treatment/prevention and FAD strategy, persistent tick control, labelled repellency against Ixodes ticks, sand flies and Aedes mosquitoes, and indirect reduction of Leishmania infantum transmission risk · On the skin
Care settingExact weight-band monthly pipette after weighing and parasite-risk assessment; divide across four intact-skin sites, prevent licking and separate from cats until dry
vetman score 8.3/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 173-11 · Verified on 15 Oct 2026

A well-documented broad canine ectoparasiticide with exact-product flea and tick studies plus useful vector repellency. Choose it for the combined clinical role, respect the delayed or incomplete protection against some vectors, and treat feline exposure prevention as mandatory.

Regulatory and scientific credibility9.0/10

All four exact presentations are registered in Georgia and covered by current regulator-hosted product literature, valid multinational authorisations and a transparent exact-product hybrid dossier with dose-confirmation studies.

Clinical efficacy8.5/10

Exact-product GCP studies support four-week flea activity and persistent efficacy against the labelled ticks, while applicable controlled and field studies support the imidacloprid-permethrin vector role. Immediate tick efficacy was not demonstrated, duration varies by target and bites or transmission are not completely prevented.

Safety and tolerability7.5/10

Healthy dogs tolerated the label dose and even five-fold overdose well in the dossier, with very rare canine reactions. The clinically important limits are potentially fatal feline permethrin exposure, reproductive uncertainty linked to N-methylpyrrolidone and aquatic toxicity.

Clinical practicality8.0/10

A weight-band pipette provides roughly monthly control, but four-site application, drying, cat separation, bathing timing, vector-onset limitations and seasonal repeat treatment add meaningful handling steps.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Never use on cats. Permethrin exposure is extremely poisonous and can be fatal; keep treated dogs away until the site is dry and seek veterinary advice immediately if a cat contacts or grooms it.
  • Do not use below seven weeks of age, outside the exact presentation weight band or in known hypersensitivity. Weigh accurately and apply only to intact skin.
  • Single ticks or vector bites may still occur and pathogen transmission cannot be excluded. Mosquito repellency begins at day 7; keep dogs protected during the first 24 hours after the initial application for the Leishmania-risk claim.
  • Ticks already present may remain attached and alive for two days; remove them manually. Exact-product studies did not demonstrate immediate tick efficacy.
  • Very rare reactions include local pruritus, erythema, oedema or hair loss, behavioural or gastrointestinal signs and neurologic signs. Prevent licking; oral exposure may cause vomiting, tremor or incoordination.
  • Safety in pregnancy, lactation and breeding animals is not established, and N-methylpyrrolidone was foetotoxic in laboratory species; use only after veterinary benefit-risk assessment and consult before use in sick or debilitated dogs.
  • Keep treated dogs out of surface water for 48 hours. Frequent or prolonged water exposure may reduce persistence, shampoo should be used before treatment or at least two weeks later, and post-wetting tick efficacy is unstudied.
  • No medicinal interactions or major incompatibilities are known in the current product literature.
  • For the 2000 mg/400 mg presentation, pregnant women or women who may be pregnant must not administer the product; women of childbearing age should wear gloves because of the N-methylpyrrolidone content.
Assessment sources
  1. VMD Ataxxa product literature2026
  2. VMD Ataxxa assessment2018
  3. European tick field RCT2016
  4. Vector-borne disease field study2010
  5. Canine leishmaniosis field trial2007
  6. Sand-fly repellent study2007
  7. Mosquito repellent study2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Permethrin2000 mg Imidacloprid400 mg
Formulation Type
Spot-on
Administration route
On the skin
Manufacturer
KRKA · Slovenia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ატაქსა® გარეგანი დასაწვეთებელი ხსნარი ძაღლებისათვის
№ 173-11
Verified on: 15 Oct 2026
 EU Yes, veterinary
Verified on: 15 Oct 2026
 UK Yes, veterinary
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
No dose for this species
Do not use this product in cats.
 Cat Any weight On the skin - Product label (SPC)
1 pipette
>25 kg <= 40 kg Ataxxa 2000 mg/400 mg spot-on solution for dogs over 25 kg 4.0 ml 10 - 16 [mg/kg imidacloprid] 50 - 80 [mg/kg permethrin] For dogs > 40 kg the appropriate combination of pipettes should be used.
 Dog 25–40 kg On the skin every 4 weeks Product label (SPC)
Active substance doses, with sources
Active substance Permethrin
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
50 mg/kg Dog Maintenance On the skin according to the epidemiological situation
VMD SPC 2026
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advantix 40 mg + 200 mg spot-on solution for dogs (<= 4 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026
60 mg/kg Dog Maintenance On the skin not more often than once every 4 weeks
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Effitix 26.8 mg/240 mg spot-on solution for very small dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Active substance Imidacloprid
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
10–25 mg/kg Dog Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 400 mg + 100 mg spot-on solution for extra-large dogs (> 25-40 kg) - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
10–20 mg/kg Cat Maintenance On the skin monthly
VMD SPC 2025
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Advocate 40 mg + 4 mg spot-on solution for small cats (<= 4 kg) and ferrets - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025

Known Contraindications

  • Critical Imidacloprid
    Do not use in cases of hypersensitivity to the active substances or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Permethrin
    Do not use in cases of hypersensitivity to the active substances, or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical Permethrin (Cat)
    Do not use on cats. This veterinary medicinal product is extremely poisonous to cats and could be fatal due to the unique physiology of cats which is unable to metabolise certain compounds including permethrin. To prevent cats from being accidentally exposed to the veterinary medicinal product, keep treated dogs away from cats after treatment until the application site is dry. It is important to ensure that cats do not groom the site of application on a dog, which has been treated with this veterinary medicinal product. Seek veterinary advice immediately if this occurs. Do not use on rabbits and cats as adverse reactions and even death can occur In case of accidental dermal exposure, wash the cat with shampoo or soap, and seek veterinary advice rapidly.
    Sources: VMD SPC · VMD
  • Warning Permethrin (Dog)
    In the absence of available data the veterinary medicinal product should not be used on puppies of less than 7 weeks of age or 1.5 kg of weight. The safety of the product has not been established in dogs younger than 12 weeks of age or in dogs weighing less than 1.5 kg.
    Sources: VMD SPC · VMD
  • Caution Permethrin (Dog)
    Can be used during pregnancy and lactation. The safety of the veterinary medicinal product has not been established in dogs during pregnancy, lactation or in animals intended for breeding. Laboratory studies in rabbits and rats with the excipient N-methyl pyrrolidone have shown evidence of foetotoxic effects. Use only according to the benefit-risk assessment by the responsible veterinarian. The safety of the veterinary medicinal product has not been established during pregnancy and lactation in bitches. Use in pregnancy and lactation only in accordance with professional veterinary advice and a benefit/risk assessment.
    Sources: VMD SPC · VMD
  • Caution Permethrin (Dog)
    Can be used during pregnancy and lactation. Use only according to the benefit-risk assessment by the responsible veterinarian.
    Sources: VMD SPC · VMD

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (80 more) Hide additional products

Same therapeutic group 80

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗